<DOC>
	<DOCNO>NCT00456508</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety repeat dos ecallantide treatment acute attack hereditary angioedema allow HAE patient continue access ecallantide . In addition , patient enrol DX-88/20 ( EDEMA4 ) trial follow treated subsequent attack trial .</brief_summary>
	<brief_title>Safety Efficacy Study Repeated Doses DX-88 ( Ecallantide ) Treat Attacks Hereditary Angioedema ( HAE )</brief_title>
	<detailed_description>This open label trial . The study design assess efficacy safety 30 mg subcutaneous ecallantide treatment acute attack hereditary angioedema . This study design provide efficacy safety data repeat use ecallantide . These data intend support marketing authorization ecallantide treatment acute attack hereditary angioedema . Efficacy safety ecallantide evaluate study .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>10 year age older Documented diagnosis HAE ( Type I II ) Willing able give inform consent Acute HAE attack time presentation Receipt investigational drug device , within 30 day prior study treatment , DX88 ( ecallantide ) Pregnancy breastfeed Receipt noninvestigational C1INH DX88 within 72 hour treatment Patients eligible current , ongoing clinical trial DX 88 ( ecallantide ) offer</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>